引用本文
  • 文松,阮氏琼娥,贺艳菊,等.钠-葡萄糖共转运体2抑制剂改善心力衰竭的研究进展[J].同济大学学报(医学版),2021,42(1):130-135.    [点击复制]
  • WEN Song,NGUYEN Thiquynhnga,HE Yan-ju,et al.Progress in study on alleviation of heart failure with sodium-glucose cotransporter 2 inhibitors[J].同济大学学报(医学版),2021,42(1):130-135.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 40次   下载 32 本文二维码信息
码上扫一扫!
钠-葡萄糖共转运体2抑制剂改善心力衰竭的研究进展
文松,阮氏琼娥,贺艳菊,周里钢
0
(上海市浦东医院·复旦大学附属浦东医院内分泌科,上海201399;上海市浦东医院·复旦大学附属浦东医院内分泌科,上海201400;上海市浦东医院·复旦大学附属浦东医院内分泌科,上海201401;上海市浦东医院·复旦大学附属浦东医院内分泌科,上海201402)
摘要:
当前诸多临床试验证明降糖新药钠-葡萄糖共转运体2抑制剂(sodium-glucose cotransporter 2 inhibitors, SGLT-2i)具有改善2型糖尿病患者心力衰竭结局的作用,其改善心力衰竭除了抑制肾脏重吸收葡萄糖而改善代谢、降低体重外,还参与心血管系统活动调节,但这种作用包含的中枢机制目前还不完全明了。有研究提出SGLT-2i可能通过影响能量代谢和心血管中枢活动而调节心血管活动,是除了减少血容量外的一个重要机制。因此本文将进一步对心血管中枢的神经内分泌调节、SGLT-2i对该系统影响的相关机制进行以下方面的综述: (1) 心血管机能的中枢神经系统调节;(2) 中枢钠葡萄糖转运体(sodium glucose cotransporter, SGLT)的分布及作用;(3) SGLT-2i心血管获益的外周机制研究进展;(4) SGLT-2i对中枢的影响作用及机制研究进展。
关键词:  中枢神经系统  能量代谢  心血管控制区域  钠-葡萄糖共转运体2抑制剂  心力衰竭
DOI:10.12289/j.issn.1008-0392.20118
投稿时间:2020-03-15
基金项目:上海市中西医结合项目(ZHYY-ZXYJHZX-2-201712);上海市浦东新区领先人才项目(PWR12014-06);上海市浦东新区卫生系统重点学科群建设资助(PWZ-xq2017-09);上海市浦东新区中西医重点专科(PWZzK2017-03;上海市浦东医院重点学科项目(Zdxk2020-11);上海市浦东医院重点专病(Zdzk2020-24)
Progress in study on alleviation of heart failure with sodium-glucose cotransporter 2 inhibitors
WEN Song,NGUYEN Thiquynhnga,HE Yan-ju,ZHOU Li-gang
(Dept. of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China;Dept. of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201400, China;Dept. of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201401, China;Dept. of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201402, China)
Abstract:
Currently, clinical studies have revealed that the novel antidiabetic agent sodium-glucose cotranspotor 2 inhibitor (SGLT-2i) can improve the outcome of heart failure in patients with type 2 diabetes mellitus (T2DM). This drug have hypoglycemic effect mediated by inhibition of glucose reabsorption by kidney, which not only improves metabolism, reduces body weight, but also regulates activity of cardiovascular system. However, the pertinent central mechanism remains unclear. In recent years, some studies have proposed that SGLT-2i probably influences the neural energy metabolism and cardiovascular control beside blood volume depletion. This article reviews the neuroendocrine mechanisms of central cardiovascular control of SGLT-2i from the following aspects: (1) the central regulation of cardiovascular activity; (2) the central distribution and associated role of SGLT; (3) the peripheral mechanism of cardiovascular benefits of SGLT-2i; and (4) the central implication and mechanism of SGLT-2i.
Key words:  central nervous system  energy metabolism  cardiovascular control center  sodium-glucose cotransporter 2 inhibitors  heart failure

您是第2554249位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计